Key result
Oral valiltramiprosate maintains cognitive stability over 4 years in biomarker-positive APOE4 carriers with mild cognitive impairment.
May support stability in APOE4 MCI; leaves open phase 3 confirmation before practice change.
Evaluate long-term efficacy of valiltramiprosate/ALZ-801 in early AD
No takes yet. Share an insight, caveat, or question.
Kesslak et al. (2026) studied this question. Oral valiltramiprosate/ALZ-801 treatment maintained cognitive stability over 4 years in biomarker-positive APOE4 carriers with mild cognitive impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Neurology